Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
Top Page
Arecor Therapeutics PLC
(LSE:AREC)
Select Model
Select Model
Rating:56Neutral
Price Target:
84.00 p
▼(-1.18% Downside)
Action:ReiteratedDate:12/07/25
Arecor Therapeutics' score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
Positive Factors
Strategic partnerships & IP expansion
Partnerships and an expanding IP portfolio create durable commercial pathways via licensing, milestones and royalties, reducing single-product risk. Stronger board governance supports execution and access to partners, improving long-term dealflow and funding diversification.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flows indicate ongoing cash burn that will require external financing or dilutive raises. Over a multi-month horizon this constrains strategic flexibility, increases financing risk, and can delay commercialization or scale-up of partnered products.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic partnerships & IP expansion
Partnerships and an expanding IP portfolio create durable commercial pathways via licensing, milestones and royalties, reducing single-product risk. Stronger board governance supports execution and access to partners, improving long-term dealflow and funding diversification.
Read all positive factors
Arecor Therapeutics PLC (AREC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£25.86M
Dividend YieldN/A
Average Volume (3M)40.10K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth3.31%
EPS Growth21.91%
CountryUK
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.07
Shares Outstanding37,756,600
10 Day Avg. Volume67,644
30 Day Avg. Volume40,099
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)4.59
Price to Sales (P/S)4.86
P/FCF Ratio-2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)£1.20M
Arecor Therapeutics PLC Business Overview & Revenue Model
Company Description
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in...
How the Company Makes Money
Arecor Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which often involve licensing agreements for its proprietary technology and products. The company may also receive milest...
Arecor Therapeutics PLC Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.06M | 5.05M | 4.57M | 2.40M | 1.16M | 1.70M |
| Gross Profit | -344.00K | 1.54M | 4.57M | 2.40M | 1.16M | 1.70M |
| EBITDA | -8.02M | -10.15M | -8.39M | -10.06M | -6.27M | -3.26M |
| Net Income | -8.10M | -10.24M | -8.55M | -9.26M | -6.17M | -2.75M |
Balance Sheet | ||||||
| Total Assets | 5.25M | 8.72M | 15.38M | 21.77M | 20.92M | 4.28M |
| Cash, Cash Equivalents and Short-Term Investments | 1.89M | 3.26M | 6.75M | 12.81M | 18.32M | 2.90M |
| Total Debt | 173.00K | 232.00K | 338.00K | 288.00K | 231.00K | 2.00M |
| Total Liabilities | 2.39M | 3.37M | 5.85M | 4.31M | 2.37M | 3.51M |
| Stockholders Equity | 2.86M | 5.35M | 9.53M | 17.45M | 18.55M | 773.79K |
Cash Flow | ||||||
| Free Cash Flow | -6.20M | -9.18M | -5.99M | -11.13M | -5.52M | -1.91M |
| Operating Cash Flow | -6.09M | -9.15M | -5.84M | -10.78M | -5.45M | -1.86M |
| Investing Cash Flow | 1.00K | 1.72M | 6.52M | -7.99M | -68.00K | -49.32K |
| Financing Cash Flow | 5.64M | 5.65M | -180.00K | 5.16M | 20.93M | 1.77M |
Arecor Therapeutics PLC Technical Analysis
Negative
85.00
Price Trends
75.00
Negative
76.47
Negative
69.62
Negative
Market Momentum
-2.32
Positive
32.59
Neutral
20.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AREC, the sentiment is Negative. The current price of 85 is above the 20-day moving average (MA) of 70.60, above the 50-day MA of 75.00, and above the 200-day MA of 69.62, indicating a bearish trend. The MACD of -2.32 indicates Positive momentum. The RSI at 32.59 is Neutral, neither overbought nor oversold. The STOCH value of 20.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AREC.
Arecor Therapeutics PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £72.36M | 9.42 | 66.44% | 8.33% | -3.61% | -6.35% | |
56 Neutral | £25.86M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | £16.57M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
43 Neutral | £695.02M | -22.92 | -82.57% | ― | 55.44% | 75.77% | |
42 Neutral | £299.62M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £16.86M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:AREC
Arecor Therapeutics PLC
68.50
20.50
42.71%
GB:AVCT
Avacta Group plc
68.50
31.00
82.67%
GB:BVXP
Bioventix
1,385.00
-1,190.05
-46.21%
GB:OXB
Oxford BioMedica
575.00
264.50
85.19%
GB:FAB
Fusion Antibodies Plc
13.25
6.75
103.85%
GB:APTA
Aptamer Group Plc
0.63
0.36
131.48%
Arecor Therapeutics PLC Corporate Events
Business Operations and Strategy
Arecor and Sequel Med Tech to Host Virtual Panel on Future of Diabetes Treatment
Positive
Jan 6, 2026
Arecor Therapeutics has announced that it will co-host a virtual fireside panel discussion with Sequel Med Tech on 7 January 2026 to explore the future of the treatment journey for people with diabetes and the factors driving innovation in diabete...
Business Operations and StrategyProduct-Related Announcements
Arecor and Sequel to Discuss Future of Insulin Delivery Systems
Positive
Dec 9, 2025
Arecor Therapeutics PLC and Sequel Med Tech LLC are set to host a virtual fireside panel discussion on January 7, 2025, focusing on the treatment journey for diabetes patients and the future of insulin delivery systems. The discussion will highlig...
Business Operations and StrategyProduct-Related Announcements
Arecor Therapeutics Expands IP Portfolio with New Patents for Diabetes Innovations
Positive
Nov 4, 2025
Arecor Therapeutics has strengthened its intellectual property (IP) portfolio with new patents for its lead product, AT278, and its oral peptide delivery technology. The US and European patents for AT278, an ultra-concentrated and ultra-rapid acti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.